Blockbuster GLP-1 drugs such as Ozempic are changing the way we look at weight loss. The Globe’s ongoing Skinny Inc. series is examining what that looks like from all sides, from how we talk about body positivity to the ways these drugs are marketed to the public. Today’s episode of the The Decibel focuses on Ozempic’s Canadian connection: Dr. Daniel Drucker is the researcher who helped pave the way for the drug, and has been studying its active ingredient, semaglutide, in the body for decades. Listen here for more, and tune in next week for the next episode in the series.

Also this week, another reason to follow the Mediterranean diet: new research shows it can help reduce stroke risk in women. Read more.

From food and drink to parenting and relationships, The Globe and Mail publishes several newsletters designed to keep you healthy, active, and informed. Visit our signup page to subscribe.